Heparin Safety During Pregnancy

Fetal Safety Profile

The American College of Cardiology recommends heparin as a safe anticoagulant during pregnancy due to its inability to cross the placental barrier, eliminating direct fetal exposure 1, 2, 3
Heparin therapy has no teratogenic potential, unlike warfarin which causes embryopathy in 4-10% of exposed pregnancies 1, 2, 4
The American College of Cardiology guidelines state that heparin therapy is "safe for the fetus" 1, 2, 3
No risk of fetal bleeding complications exists with heparin therapy, whereas warfarin can cause fetal cerebral hemorrhage during delivery 1, 5

The American College of Cardiology notes that heparin is less effective than warfarin for preventing maternal thromboembolism, particularly in high-risk patients with mechanical heart valves 1, 2, 3
Heparin leads to a 12-24% incidence of thromboembolic complications, including fatal valve thrombosis in women with prosthetic valves 1, 2, 5
Maternal thromboembolism and death risks more than double when heparin is used during the first trimester in high-risk patients 1, 2, 4
Osteoporosis risk exists with long-term heparin therapy, though less common with low-molecular-weight heparin (LMWH) than unfractionated heparin (UFH) 1, 2

The American College of Cardiology recommends using heparin during the first trimester to avoid warfarin embryopathy 1, 2, 4
The European Heart Journal notes that warfarin during the first trimester is actually safer for the mother despite fetal risks, given the prohibitively high maternal thromboembolism rate with heparin 6, 7, 8

The American College of Cardiology recommends measuring anti-Xa levels 4-6 hours after morning dose for LMWH dosing adjustment 1, 2, 3
Target anti-Xa level of 0.7-1.2 units/mL for LMWH therapy 1, 2, 5
Monitor aPTT response for UFH, though it may be attenuated during pregnancy due to elevated factor VIII and fibrinogen 1, 2, 4

Neither unfractionated heparin (UFH) nor low-molecular-weight heparin (LMWH) cross the placental barrier, and neither is found in breast milk in significant amounts, according to the European Heart Journal 9

Low-molecular-weight heparin offers significant advantages including no monitoring requirement and reduced risk of osteoporosis and heparin-induced thrombocytopenia compared to UFH, as stated in the European Heart Journal 9
The typical LMWH dose is either 200 IU/kg once daily or 100 IU/kg twice daily, as recommended by the European Heart Journal 9

For UFH given subcutaneously twice daily, target aPTT should be 1.5-2.5 times control, measured 6 hours after injection, according to the European Heart Journal 9

Subcutaneous heparin injections should be discontinued at the onset of regular uterine contractions, as recommended by the European Heart Journal 9, 10, 11
The use of epidural analgesia in patients who received heparin within the previous 12-24 hours is debated due to epidural hematoma risk, though this risk is probably very low, as discussed in the European Heart Journal 9, 10, 11